Puri P, Granata C
Children's Research Centre, Our Lady's Hospital for Sick Children, Dublin, Ireland.
J Urol. 1998 Sep;160(3 Pt 2):1007-11; discussion 1038. doi: 10.1097/00005392-199809020-00011.
Endoscopic subureteral polytetrafluoroethylene (Teflon) injection has been used successfully to treat primary and secondary vesicoureteral reflux in children. We review the results of subureteral polytetrafluoroethylene injection in terms of its effectiveness, long-term followup and morbidity.
A total of 53 pediatric urologists and/or pediatric surgeons at 41 centers worldwide answered an inquiry regarding experience with subureteral polytetrafluoroethylene injection in vesicoureteral reflux. Data were collected from a completed standard questionnaire. From 1984 to 1996, 1,921 boys and 6,411 girls with a mean age of 4.5 years (12,251 refluxing ureters) were treated endoscopically with subureteral polytetrafluoroethylene injection. Reflux was grades I to V in 407 (3.3%), 3,832 (31.2%), 5,213 (42.5%), 2,218 (18.1%) and 581 (4.7%) ureters, respectively. In the majority of patients subureteral polytetrafluoroethylene injection was performed on an outpatient basis. Most urologists monitored patients with voiding cystourethrography and renal ultrasound at 3 months, 1 year and 3 years. All patients were followed 1 to 13 years.
Reflux resolved in 9,226 ureters (75.3%) after 1 polytetrafluoroethylene injection, in 1,478 (12%) after 2 and in 250 (2%) after 3 or 4. Vesicoureteral reflux improved to grade I after 1 or 2 injections in 743 (6%) ureters, which needed no further treatment. Subureteral injection failed to correct reflux in 554 ureters (4.5%), which were then treated with ureteral reimplantation. Vesicoureteral junction obstruction requiring ureteral reimplantation developed in 41 ureters (0.33%). More than 90% of patients have been followed for more than 2 years. At followup reflux recurred in 326 (2.8%) endoscopically corrected refluxing ureters. No clinically untoward effects were reported in any patient due to the use of polytetrafluoroethylene as an injectable material.
The results of this multicenter survey confirm that endoscopic subureteral polytetrafluoroethylene injection is a simple, safe and effective outpatient procedure for treating all grades of vesicoureteral reflux.
内镜下输尿管下聚四氟乙烯(特氟龙)注射已成功用于治疗儿童原发性和继发性膀胱输尿管反流。我们根据其有效性、长期随访及发病率来回顾输尿管下聚四氟乙烯注射的结果。
全球41个中心的53名儿科泌尿科医生和/或儿科外科医生回答了一份关于输尿管下聚四氟乙烯注射治疗膀胱输尿管反流经验的询问。数据来自一份完整的标准问卷。1984年至1996年,1921名男孩和6411名女孩(平均年龄4.5岁,共12251条反流输尿管)接受了输尿管下聚四氟乙烯注射的内镜治疗。反流分别为I至V级的输尿管有407条(3.3%)、3832条(31.2%)、5213条(42.5%)、2218条(18.1%)和581条(4.7%)。大多数患者在门诊接受输尿管下聚四氟乙烯注射。大多数泌尿科医生在3个月、1年和3年时通过排尿性膀胱尿道造影和肾脏超声对患者进行监测。所有患者随访1至13年。
1次聚四氟乙烯注射后9226条输尿管(75.3%)反流消失,2次注射后1478条(12%)反流消失,3次或4次注射后250条(2%)反流消失。1次或2次注射后743条输尿管(6%)的膀胱输尿管反流改善至I级,无需进一步治疗。输尿管下注射未能纠正554条输尿管(4.5%)的反流,这些输尿管随后接受了输尿管再植术。41条输尿管(0.33%)出现需要输尿管再植术的膀胱输尿管连接部梗阻。超过90%的患者随访时间超过2年。随访时,326条(2.8%)经内镜纠正反流的输尿管反流复发。没有患者报告因使用聚四氟乙烯作为可注射材料而出现临床不良反应。
这项多中心调查结果证实,内镜下输尿管下聚四氟乙烯注射是一种治疗各级膀胱输尿管反流的简单、安全且有效的门诊手术。